- Credit Amounts:
- CME: 1.00
- CPE: 1.00
- CHES: 1.00
- CNE: 1.00
- Cost: Free
- Release: Nov 15, 2023
- Expires: Nov 15, 2026
- Estimated Time to Complete:
1 Hour(s) -
Average User Rating:
( Ratings)
Faculty
Click Here to View All
Chief Medical Officer
UnitedHealthcare Medicaid Kentucky
Louisville, Kentucky
Associate Professor, Pediatrics
University of Kentucky College of Medicine
Director
UK HealthCare CECentral
Lexington, Kentucky
Associate Dean & Professor of Pharmacy
Paul F. Parker Endowed Professor of Pharmacy
University of Kentucky College of Pharmacy
Lexington, Kentucky
Professor of Medicine
University of Kentucky College of Medicine Chief of the Division of Infectious Diseases University of Kentucky Medical Center Lexington, Kentucky
Associate Professor
Associate Division Chief
Division of Infectious Diseases
University of Kentucky
Lexington, Kentucky
Needs Statement
The CDC has newly issued recommendations for the monovalent COVID booster targeting new strains for everyone older than 6 months of age. In addition, there are two new RSV vaccines, one for infants and one for adults. These illnesses account for high levels of hospitalizations while vaccination rates remain low.The RSV vaccines are new this year and healthcare teams need to gain knowledge of recommendations, effectiveness, and side effects for these new agents. In addition, teams need to be made aware of new recommendations for the new COVID booster.
COVID vaccinations rates remain relatively low in KY (~69% having at least one dose) and there is misinformation around side effects and importance of vaccination with both COVID and RSV vaccines. Healthcare teams need to know how to address misinformation related to fall respiratory virus vaccines.
Target Audience
All healthcare teams members who are direct contact with patients who administer and/or provide knowledge about vaccines.Objectives
Upon completion of this activity, participants will be able to:1. Discuss the impact of RSV and COVID on the health of adults
2. Describe RSV and COVID vaccine effectiveness, side effects, and current guidelines
3. Address myths related to RSV and COVID vaccines
Accreditation
In support of improving patient care, this activity has been planned and implemented by UK HealthCare CECentral and Kentucky Association of Health Plans. University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME
This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
CPE
This knowledge-based activity will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.
CHES
Sponsored by Department of Public Health, Western Kentucky University, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced-level continuing education contact hours available are 0. Continuing Competency credits available are 0. Provider ID# 105862 Event ID# 61051
CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour.
Faculty Disclosure
All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.
Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.